Little has gone right for Mylan recently, so the company and its investors can be forgiven for embracing a new drug as its next engine for growth.
WSJ.com: Markets, Wall Street Journal: Markets: Market News
Mon, 11/06/2017 - 10:19am
Little has gone right for Mylan recently, so the company and its investors can be forgiven for embracing a new drug as its next engine for growth.